Cash Flow Statement

Beginning Cash Balance Beginning Cash Balance Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mangoceuticals (MGRX) Capital Expenditures (2023)

Mangoceuticals' Capital Expenditures history spans 1 years, with the latest figure at $3519.0 for Q1 2023.

On a quarterly basis, Capital Expenditures changed N/A to $3519.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $3519.0, a N/A change, with the full-year FY2023 number at $3519.0, changed N/A from a year prior.
Capital Expenditures hit $3519.0 in Q1 2023 for Mangoceuticals.
Over the last five years, Capital Expenditures for MGRX hit a ceiling of $3519.0 in Q1 2023 and a floor of $3519.0 in Q1 2023.